I-Mab will become a completely US-based company, divesting itself of I-Mab Biopharma (Hangzhou), an unconsolidated affiliate. I-Mab Hangzhou will acquire rights to I-Mab’s drug assets in Greater China for $80 million.

Eisai Co Ltd’s most recent $0.14 semi-annual dividend, paid June 12th to shareholders of record March 30th, equates to $0.28 annually and throws a yield of 1.74% as of Friday’s closing price.

Bliss Biopharma may out-license global rights for its HER2 ADC to Eisai Pharma in a deal with a potential value of $2 billion. Also, Junshi Bio out-licensed regional rights for its anti-PD-1 mAb to Dr. Reddy’s Labs in a deal worth up to $728 million.